|Bid||20.01 x 0|
|Ask||20.15 x 0|
|Day's Range||19.90 - 20.69|
|52 Week Range||7.33 - 32.95|
|Beta (3Y Monthly)||4.70|
|PE Ratio (TTM)||36.10|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.52|
Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) heads up a list of top Canadian legal marijuana stocks to snap up at the moment.
The Wisconsin Retirement System, one of only two fully funded state pensions, also slashed its holdings in PG&E, the struggling California utility, last quarter.
Wall Street has handed out not one, two, or three... but seven price-target cuts to this marijuana stock since the month began.
The advocacy group Smart Approaches to Marijuana (SAM) is pushing for a middle road approach, aiming for decriminalization without risking any unintended consequences of full legalization.
Cronos Group Inc. (TSX:CRON) (NASDAQ:CRON) recently released disappointing financial results. Here is why the pot company isn't worth the trouble.
MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.
Cannabis cultivation requires enormous amounts of energy, and water, and the companies that employ smart solutions are now pulling ahead in the highly competitive cannabis boom
The Market Is Sinking and Taking the Cannabis Sector Along(Continued from Prior Part)Cronos declinesCronos Group (CRON) underwent a deep selloff after it reported its earnings last week, and it lost another 7% during the day. See Cronos Group:
High valuations and a growing competition indicate that it may be time to short Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) and Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON).
Cannabis Sector Fell on CRON's Earnings and Trade TensionsCannabis sector last week Last week was lackluster for the cannabis sector, and most of the stocks in the sector ended in the negative territory.
Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) posted some strong numbers in Q1, so why weren't investors more excited about the results?
Aurora is taking the road less traveled in finding a partner outside of the cannabis industry. But could the road be dead-end?
Women in the cannabis industry use various tactics to counter the stigma of working in the nascent field.
Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) and The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) are two cannabis companies that investors are seriously looking at, but are they looking to buy or sell?
Canadian cannabis vendor (CRON) has $2 billion in its pocket and yet says it can’t find enough good marijuana. The company blamed a shortage of suitable product on Canada’s wholesale market for its paltry $4 million in marijuana sales in the most recent quarter.